Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ensysce Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ENSC
Nasdaq
8731
https://ensysce.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ensysce Biosciences Inc
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
- Apr 19th, 2024 12:00 pm
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
- Apr 9th, 2024 12:00 pm
ENSC Striding Toward Opioid Replacement
- Mar 15th, 2024 12:07 pm
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 15th, 2024 12:00 pm
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
- Feb 27th, 2024 1:00 pm
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
- Feb 21st, 2024 1:00 pm
ENSC: Investors Should Pay Attention
- Feb 16th, 2024 10:07 am
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
- Feb 15th, 2024 1:00 pm
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
- Feb 13th, 2024 1:00 pm
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
- Feb 6th, 2024 1:00 pm
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
- Jan 31st, 2024 1:00 pm
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
- Jan 25th, 2024 1:00 pm
Opioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's Why
- Jan 23rd, 2024 8:13 pm
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
- Jan 23rd, 2024 1:00 pm
ENSC Announces Major FDA Designation
- Jan 23rd, 2024 10:20 am
Ensysce Biosciences Issues 2024 Shareholder Letter
- Jan 8th, 2024 1:15 pm
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
- Dec 19th, 2023 9:15 pm
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
- Dec 14th, 2023 1:15 pm
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
- Dec 11th, 2023 2:00 pm
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
- Nov 29th, 2023 1:05 pm
Scroll